{
    "eid": "2-s2.0-85108623668",
    "title": "Therapeutic drug monitoring of immunosuppressive drugs in hepatology and gastroenterology",
    "cover-date": "2021-10-01",
    "subject-areas": [
        {
            "@_fa": "true",
            "$": "Gastroenterology",
            "@code": "2715",
            "@abbrev": "MEDI"
        }
    ],
    "keywords": [
        "Autoimmune hepatitis",
        "Immunosuppressants",
        "Inflammatory bowel disease",
        "Liver",
        "Therapeutic drug monitoring",
        "Transplantation"
    ],
    "authors": [
        "Suwasin Udomkarnjananun",
        "Marith I. Francke",
        "Brenda C.M. De Winter",
        "Midas B. Mulder",
        "Carla C. Baan",
        "Herold J. Metselaar",
        "Caroline M. den Hoed",
        "Dennis A. Hesselink"
    ],
    "citedby-count": 10,
    "ref-count": 139,
    "ref-list": [
        "Therapeutic drug monitoring - key to personalized pharmacotherapy",
        "Improving therapeutic decisions: pharmacodynamic monitoring as an integral part of therapeutic drug monitoring",
        "KDIGO clinical practice guideline for the care of kidney transplant recipients",
        "Immunological and pharmacological monitoring in the clinical use of cyclosporin A",
        "Mycophenolate revisited",
        "TAC-TIC use of tacrolimus-based regimens in lupus nephritis",
        "Therapeutic drug monitoring in cancer\u2013are we missing a trick?",
        "Recent advances in therapeutic drug monitoring of immunosuppressive drugs",
        "On-site therapeutic drug monitoring",
        "A clinical assessment of mycophenolate drug monitoring after liver transplantation",
        "Mycophenolic acid pharmacodynamics and pharmacokinetics provide a basis for rational monitoring strategies",
        "Intra-patient variability in tacrolimus exposure: causes, consequences for clinical management",
        "OPTN/SRTR 2018 annual data report: liver",
        "Clinical pharmacokinetic and pharmacodynamic considerations in the treatment of ulcerative colitis",
        "Tacrolimus as an effective and durable second-line treatment for chronic autoimmune hepatitis: a multicentric study",
        "Effect of CYP3A and ABCB1 single nucleotide polymorphisms on the pharmacokinetics and pharmacodynamics of calcineurin inhibitors: Part I",
        "Changes in tacrolimus distribution in blood and plasma protein binding following liver transplantation",
        "PharmGKB summary: cyclosporine and tacrolimus pathways",
        "Evaluation of tacrolimus abbreviated area-under-the-curve monitoring in renal transplant patients who are potentially at risk for adverse events",
        "Intra- and interindividual variation in the pharmacokinetics of tacrolimus (FK506) in kidney transplant recipients\u2013importance of trough level as a practical indicator",
        "An abbreviated area-under-the-curve monitoring for tacrolimus in patients with liver transplants",
        "Abbreviated tacrolimus area-under-the-curve monitoring for renal transplant recipients",
        "Evaluation of a limited sampling strategy to estimate area under the curve of tacrolimus in adult renal transplant patients",
        "Chronopharmacokinetics of tacrolimus in kidney transplant recipients: occurrence of acute rejection",
        "Evaluation of limited sampling strategies for tacrolimus",
        "AUC-guided dosing of tacrolimus prevents progressive systemic overexposure in renal transplant recipients",
        "Calcineurin activity assay measurement by liquid chromatography-tandem mass spectrometry in the multiple reaction monitoring mode",
        "Pharmacodynamic analysis of tacrolimus and cyclosporine in living-donor liver transplant patients",
        "NFAT-regulated cytokine gene expression during tacrolimus therapy early after renal transplantation",
        "Reduced residual gene expression of nuclear factor of activated T cells-regulated genes correlates with the risk of cytomegalovirus infection after liver transplantation",
        "Analysis of NFATc1 amplification in T cells for pharmacodynamic monitoring of tacrolimus in kidney transplant recipients",
        "Tacrolimus predose concentrations do not predict the risk of acute rejection after renal transplantation: a pooled analysis from three randomized-controlled clinical trials(\u2020)",
        "FK506 trough levels in whole blood and plasma in liver transplant recipients. Correlation with clinical events and side effects",
        "Tacrolimus trough levels, rejection and renal impairment in liver transplantation: a systematic review and meta-analysis",
        "Pharmacokinetics, efficacy, and safety of mycophenolate mofetil in combination with standard-dose or reduced-dose tacrolimus in liver transplant recipients",
        "Practical recommendations for long-term management of modifiable risks in kidney and liver transplant recipients: a guidance report and clinical checklist by the consensus on managing modifiable risk in transplantation (COMMIT) group",
        "The renal-sparing efficacy of basiliximab in adult living donor liver transplantation",
        "Delayed introduction of reduced-dose tacrolimus, and renal function in liver transplantation: the 'ReSpECT' study",
        "International liver transplantation society consensus statement on immunosuppression in liver transplant recipients",
        "Immunosuppressive regimens for adult liver transplant recipients in real-life practice: consensus recommendations from an Italian Working Group",
        "Both tacrolimus and mycophenylate mophetil should be considered second-line therapy for autoimmune hepatitis",
        "Second-line and third-line therapy for autoimmune hepatitis: a position statement from the European reference Network on hepatological diseases and the international autoimmune hepatitis group",
        "Clinical pharmacogenetics implementation consortium (CPIC) guidelines for CYP3A5 genotype and tacrolimus dosing",
        "Differences in CYP3A genotypes of a liver transplant recipient and the donor liver graft and adjustment of tacrolimus dose",
        "Meta-analysis and systematic review of the effect of the donor and recipient CYP3A5 6986A>G genotype on tacrolimus dose requirements in liver transplantation",
        "Effects of combinational CYP3A5 6986A>G polymorphism in graft liver and native intestine on the pharmacokinetics of tacrolimus in liver transplant patients: a meta-analysis",
        "A new functional CYP3A4 intron 6 polymorphism significantly affects tacrolimus pharmacokinetics in kidney transplant recipients",
        "Therapeutic drug monitoring of tacrolimus-personalized therapy: second consensus report",
        "Optimization of initial tacrolimus dose using pharmacogenetic testing",
        "Improved tacrolimus target concentration achievement using computerized dosing in renal transplant recipients\u2013A prospective, randomized study",
        "Avoiding tacrolimus under- and overexposure with a dosing algorithm for renal transplant recipients: a single arm prospective intervention trial",
        "A randomized controlled trial comparing the efficacy of Cyp3a5 genotype-based with body-weight-based tacrolimus dosing after living donor kidney transplantation",
        "Individualised medicine: why we need Bayesian dosing",
        "Tacrolimus exposure prediction using machine learning",
        "Estimation of drug exposure by machine learning based on simulations from published pharmacokinetic models: the example of tacrolimus",
        "A population pharmacokinetic model to predict the individual starting dose of tacrolimus following pediatric renal transplantation",
        "Pharmacokinetics and toxicity of tacrolimus early after heart and lung transplantation",
        "Drug interactions with tacrolimus",
        "Assessment of tacrolimus intrapatient variability in stable adherent transplant recipients: establishing baseline values",
        "Impact of low tacrolimus exposure and high tacrolimus intra-patient variability on the development of de novo anti-HLA donor-specific antibodies in kidney transplant recipients",
        "A comprehensive review of the impact of tacrolimus intrapatient variability on clinical outcomes in kidney transplantation",
        "The effects of intrapatient variability in tacrolimus concentration on clinical outcomes immediately after liver transplantation",
        "High tacrolimus intra-patient variability is associated with graft rejection, and de novo donor-specific antibodies occurrence after liver transplantation",
        "High intrapatient variability of tacrolimus exposure in the early period after liver transplantation is associated with poorer outcomes",
        "High intrapatient variability in tacrolimus exposure is not associated with immune-mediated graft injury after liver transplantation",
        "Intrapatient variability of tacrolimus exposure in solid organ transplantation: a novel marker for clinical outcome",
        "Lower variability of tacrolimus trough concentration after conversion from prograf to advagraf in stable kidney transplant recipients",
        "Conversion from twice-daily to once-daily tacrolimus does not reduce intrapatient variability in tacrolimus exposure",
        "Impact of laboratory practices on interlaboratory variability in therapeutic drug monitoring of immunosuppressive drugs",
        "Recent advances in analytical methods for the therapeutic drug monitoring of immunosuppressive drugs",
        "Correlation of tacrolimus levels in peripheral blood mononuclear cells with histological staging of rejection after liver transplantation: preliminary results of a prospective study",
        "Measuring intracellular concentrations of calcineurin inhibitors: expert consensus from the international association of therapeutic drug monitoring and clinical toxicology expert panel",
        "Pharmacogenetic-Whole blood and intracellular pharmacokinetic-Pharmacodynamic (PG-PK2-PD) relationship of tacrolimus in liver transplant recipients",
        "Pharmacokinetics and pharmacodynamics of tacrolimus in liver transplant recipients: inside the white blood cells",
        "Longitudinal study of tacrolimus in lymphocytes during the first year after kidney transplantation",
        "Monitoring the tacrolimus concentration in peripheral blood mononuclear cells of kidney transplant recipients",
        "Tacrolimus dose, blood concentrations and acute nephrotoxicity, but not CYP3A5/ABCB1 genetics, are associated with allograft tacrolimus concentrations in renal transplant recipients",
        "New insights into the pharmacokinetics and pharmacodynamics of the calcineurin inhibitors and mycophenolic acid: possible consequences for therapeutic drug monitoring in solid organ transplantation",
        "A comparison of mycophenolate mofetil with mycophenolate sodium in renal transplant recipients on tacrolimus-based treatment",
        "Mycophenolate mofetil versus enteric-coated mycophenolate sodium: a large, single-center comparison of dose adjustments and outcomes in kidney transplant recipients",
        "Therapeutic drug monitoring of mycophenolates in kidney transplantation: report of the Transplantation Society consensus meeting",
        "Mycophenolate, clinical pharmacokinetics, formulations, and methods for assessing drug exposure",
        "Personalized therapy for mycophenolate: consensus report by the international association of therapeutic drug monitoring and clinical toxicology",
        "Cyclosporine interacts with mycophenolic acid by inhibiting the multidrug resistance-associated protein 2",
        "Drug interactions in transplantation",
        "Mycophenolic acid (MPA) and its glucuronide metabolites interact with transport systems responsible for excretion of organic anions in the basolateral membrane of the human kidney",
        "Clinical pharmacokinetics of mycophenolate mofetil",
        "Consensus report on therapeutic drug monitoring of mycophenolic acid in solid organ transplantation",
        "Mycophenolate monitoring in liver, thoracic, pancreas, and small bowel transplantation: a consensus report",
        "Therapeutic drug monitoring of mycophenolate in adult solid organ transplant patients: an update",
        "Optimizing mycophenolic acid exposure in kidney transplant recipients: time for target concentration intervention",
        "Enteric-coated mycophenolate sodium provides higher mycophenolic acid predose levels compared with mycophenolate mofetil: implications for therapeutic drug monitoring",
        "Limited sampling model for advanced mycophenolic acid therapeutic drug monitoring after liver transplantation",
        "Pharmacodynamic assessment of mycophenolic acid-induced immunosuppression in renal transplant recipients",
        "Pre-transplant inosine monophosphate dehydrogenase activity is associated with clinical outcome after renal transplantation",
        "Pharmacodynamic assessment of mycophenolic acid in resting and activated target cell population during the first year after renal transplantation",
        "Monitoring of inosine monophosphate dehydrogenase activity and expression during the early period of mycophenolate mofetil therapy in de novo renal transplant patients",
        "The pharmacokinetic-pharmacodynamic relationship for mycophenolate mofetil in renal transplantation",
        "Impact of longitudinal exposure to mycophenolic acid on acute rejection in renal-transplant recipients using a joint modeling approach",
        "Monitoring mycophenolate in liver transplant recipients: toward a therapeutic range",
        "Individualized mycophenolate mofetil dosing based on drug exposure significantly improves patient outcomes after renal transplantation",
        "PharmGKB summary: mycophenolic acid pathway",
        "Barcelona consensus on biomarker-based immunosuppressive drugs management in solid organ transplantation",
        "Pharmacogenetics of immunosuppressant drugs: a new aspect for individualized therapy",
        "Do Asian renal transplant patients need another mycophenolate mofetil dose compared with Caucasian or African American patients?",
        "Intra-individual variability of mycophenolic acid concentration according to renal function in liver transplant recipients receiving mycophenolate monotherapy",
        "Everolimus and sirolimus in transplantation-related but different",
        "Roles of mTOR complexes in the kidney: implications for renal disease and transplantation",
        "Clinical pharmacokinetics of sirolimus",
        "Clinical pharmacokinetics of everolimus",
        "Use of everolimus in liver transplantation: recommendations from a working group",
        "A review on therapeutic drug monitoring of the mTOR class of immunosuppressants: everolimus and sirolimus",
        "A clinical pharmacokinetic study of tacrolimus and sirolimus combination immunosuppression comparing simultaneous to separated administration",
        "Pharmacokinetics of the immunosuppressant everolimus in maintenance renal transplant patients",
        "Pharmacodynamic monitoring of mTOR inhibitors",
        "Therapeutic drug monitoring of everolimus: a consensus report",
        "Therapeutic drug monitoring for everolimus in kidney transplantation using 12-month exposure, efficacy, and safety data",
        "Optimizing everolimus exposure when combined with calcineurin inhibitors in solid organ transplantation",
        "Everolimus with reduced tacrolimus improves renal function in de novo liver transplant recipients: a randomized controlled trial",
        "Sirolimus use in liver transplant recipients with hepatocellular carcinoma: a randomized, multicenter, open-label phase 3 trial",
        "Randomized sirolimus-based early calcineurin inhibitor reduction in liver transplantation: impact on renal function",
        "Impact of variability of sirolimus trough level on chronic allograft nephropathy",
        "Variability of the mammalian target of rapamycin inhibitors is correlated with long-term renal graft survival",
        "A randomized double-blind comparative study of mycophenolate mofetil and azathioprine in combination with cyclosporine and corticosteroids in primary liver transplant recipients",
        "Usage of tacrolimus and mycophenolic acid during conception, pregnancy, and lactation, and its implications for therapeutic drug monitoring: a systematic critical review",
        "Enhanced bioavailability of azathioprine compared to 6-mercaptopurine therapy in inflammatory bowel disease: correlation with treatment efficacy",
        "Azathioprine and 6-mercaptopurine pharmacogenetics and metabolite monitoring in inflammatory bowel disease",
        "Azathioprine pharmacokinetics after intravenous, oral, delayed release oral and rectal foam administration",
        "Rational dosing of azathioprine and 6-mercaptopurine",
        "Optimizing the use of thiopurines in inflammatory bowel disease",
        "British Society of Gastroenterology consensus guidelines on the management of inflammatory bowel disease in adults",
        "Systematic review and meta-analysis of thiopurine metabolite levels and biochemical remission in autoimmune hepatitis",
        "Autoimmune hepatitis: current and future therapeutic options",
        "Day-to-day variability in azathioprine pharmacokinetics in renal transplant recipients",
        "Clinical pharmacogenetics implementation consortium guideline for thiopurine dosing based on TPMT and NUDT15 genotypes: 2018 update",
        "The relationship between thiopurine S-methyltransferase genotype/phenotype and 6-thioguanine nucleotide levels in 316 patients with inflammatory bowel disease on 6-thioguanine",
        "Modeling the outcome of systematic TPMT genotyping or phenotyping before azathioprine prescription: a cost-effectiveness analysis",
        "Azathioprine-induced fatal myelosuppression in systemic lupus erythematosus patient carrying TPMT*3C polymorphism",
        "Analytical pitfalls of therapeutic drug monitoring of thiopurines in patients with inflammatory bowel disease"
    ],
    "affiliation": [
        {
            "affiliation-city": "Rotterdam",
            "@id": "60032114",
            "affilname": "Erasmus MC",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60032114",
            "affiliation-country": "Netherlands"
        },
        {
            "affiliation-city": "Rotterdam",
            "@id": "60273265",
            "affilname": "Erasmus MC Transplant Institute",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60273265",
            "affiliation-country": "Netherlands"
        },
        {
            "affiliation-city": "Bangkok",
            "@id": "60022183",
            "affilname": "King Chulalongkorn Memorial Hospital",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60022183",
            "affiliation-country": "Thailand"
        }
    ],
    "funding": [
        "Chiesi Pharma",
        "Bristol-Myers Squibb",
        "Astellas Pharma"
    ]
}